tiprankstipranks
In this article:
Blurbs

Analysts Offer Insights on Consumer Goods Companies: Aspen Group (ASPU) and PharmaCyte Biotech (PMCB)

In this article:
In this article:

Analysts fell to the sidelines weighing in on Aspen Group (ASPUResearch Report) and PharmaCyte Biotech (PMCBResearch Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.

Aspen Group (ASPU)

In a report released yesterday, Darren Aftahi from Roth Capital maintained a Hold rating on Aspen Group, with a price target of $4.00. The company’s shares closed last Tuesday at $2.61, close to its 52-week low of $2.60.

According to TipRanks.com, Aftahi is a 5-star analyst with an average return of 35.9% and a 45.3% success rate. Aftahi covers the Technology sector, focusing on stocks such as Fathom Holdings, Digital Turbine, and Argo Blockchain.

Aspen Group has an analyst consensus of Moderate Buy, with a price target consensus of $6.00.

See the top stocks recommended by analysts >>

PharmaCyte Biotech (PMCB)

In a report released today, Edward White from H.C. Wainwright maintained a Hold rating on PharmaCyte Biotech. The company’s shares closed last Tuesday at $2.40, close to its 52-week low of $2.25.

According to TipRanks.com, White is a 4-star analyst with an average return of 7.8% and a 36.8% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Silverback Therapeutics, and Karyopharm Therapeutics.

PharmaCyte Biotech has an analyst consensus of Hold.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ASPU:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed